陈育全, 林毓嫱, 白树真, 唐侍豪, 蒋文中, 刘移民, 王致. 特异性烯醇化酶、糖类抗原125、糖类抗原199对尘肺病肺纤维化进展的监测价值[J]. 职业卫生与应急救援, 2023, 41(6): 684-687. DOI: 10.16369/j.oher.issn.1007-1326.2023.06.010
引用本文: 陈育全, 林毓嫱, 白树真, 唐侍豪, 蒋文中, 刘移民, 王致. 特异性烯醇化酶、糖类抗原125、糖类抗原199对尘肺病肺纤维化进展的监测价值[J]. 职业卫生与应急救援, 2023, 41(6): 684-687. DOI: 10.16369/j.oher.issn.1007-1326.2023.06.010
CHEN Yuquan, LIN Yuhua, BAI Shuzhen, TANG Shihao, JIANG Wenzhong, LIU Yimin, WANG Zhi. Role of neuron specific enolase, carbohydrate antigen 125, and carbohydrate antigen 199 in monitoring the pulmonary fibrosis progression of pneumoconiosis[J]. Occupational Health and Emergency Rescue, 2023, 41(6): 684-687. DOI: 10.16369/j.oher.issn.1007-1326.2023.06.010
Citation: CHEN Yuquan, LIN Yuhua, BAI Shuzhen, TANG Shihao, JIANG Wenzhong, LIU Yimin, WANG Zhi. Role of neuron specific enolase, carbohydrate antigen 125, and carbohydrate antigen 199 in monitoring the pulmonary fibrosis progression of pneumoconiosis[J]. Occupational Health and Emergency Rescue, 2023, 41(6): 684-687. DOI: 10.16369/j.oher.issn.1007-1326.2023.06.010

特异性烯醇化酶、糖类抗原125、糖类抗原199对尘肺病肺纤维化进展的监测价值

Role of neuron specific enolase, carbohydrate antigen 125, and carbohydrate antigen 199 in monitoring the pulmonary fibrosis progression of pneumoconiosis

  • 摘要:
    目的 探讨尘肺病患者进行神经元特异性烯醇化酶(neuron specific enolase,NSE)、糖类抗原125(carbohydrate antigen 125,CA125)、糖类抗原199(carbohydrate antigen,CA199)监测的临床意义。
    方法 对广州市第十二人民医院尘肺科2018年1月—2022年12月收治的222例尘肺病患者进行回顾性分析,将入选患者按尘肺病期别(壹、贰、叁期)分为3组,比较各组患者血清NSE、CA125、CA199水平及异常率。
    结果 222例尘肺病患者中,壹期51例(占22.97%),贰期52例(占23.42%),叁期119例(占53.61%)。不同期别的尘肺病患者血清中NSE、CA125水平组间差异有统计学意义(P < 0.001),尘肺病叁期患者血清中NSE、CA125水平均高于壹期、贰期患者(P < 0.001)。不同期别的尘肺病患者血清中CA199水平组间差异无统计学意义(P=0.163)。222例尘肺病患者血清NSE、CA125、CA199异常率分别为45.05%、27.93%和2.70%,不同期别尘肺病患者血清中NSE、CA125异常率差异有统计学意义(均P < 0.001),均有随着期别增加而上升的趋势。
    结论 对尘肺病患者进行血清NSE、CA125的监测,有助于预判其病情的进展,为患者制定治疗方案提供参考。

     

    Abstract:
    Objective To explore the clinical significance of monitoring neuron specific enolase(NSE), carbohydrate antigen 125(CA125), and carbohydrate antigen 199(CA199) in patients with pneumoconiosis.
    Methods A retrospective analysis was conducted among 222 patients with pneumoconiosis admitted to this hospital from January 2018 to December 2022.The patients were divided into three groups according to the stage of pneumoconiosis(stage Ⅰ, Ⅱ, and Ⅲ). The serum levels and abnormal rates of NSE, CA125, and CA199 among these groups were compared.
    Results Among the 222patients with pneumoconiosis, 51(22.97%) were in stage Ⅰ, 52(23.42%) were in stage Ⅱ, and 119(53.61%) were in stage Ⅲ. There were statistically significant differences in serum NSE and CA125 levels among pneumoconiosis patients at different stages(P < 0.001), and serum NSE and CA125 levels in patients at stage Ⅲ were higher than those in stage Ⅰand stage Ⅱ(P < 0.001). There was no statistically significant difference in serum CA199 level among pneumoconiosis patients at different stages(P=0.163). The abnormal rates of serum NSE, CA125, and CA199 levels among 222 patients were 45.05%, 27.93%, and 2.70%, respectively. There were statistically significant differences in serum NSE and CA125abnormal rates among pneumoconiosis patients at different stages(both P < 0.001), and both showed an increasing trend with the increase of stage.
    Conclusions Monitoring serum NSE and CA125 in patients with pneumoconiosis can indicate the progression of their condition and provide references for the treatment plan.

     

/

返回文章
返回